Literature DB >> 24788392

Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.

Li Pan1, John L Woodard, David M Lucas, James R Fuchs, A Douglas Kinghorn.   

Abstract

Covering: 2006 to 2013. Investigations on the chemistry and biology of rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species during the period 2006-2013 are reviewed. Included are new phytochemical studies of naturally occurring rocaglamide derivatives, an update on synthetic methods for cyclopenta[b]benzofurans, and a description of the recent biological evaluation and mechanism-of-action studies on compounds of this type.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24788392      PMCID： PMC4091845          DOI： 10.1039/c4np00006d

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN： 0265-0568            Impact factor:   13.423


  76 in total

1.  A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.

Authors:  T Fahrig; I Gerlach; E Horváth
Journal:  Mol Pharmacol       Date:  2005-02-16       Impact factor: 4.436

2.  Formal synthesis of (±)-methyl rocaglate using an unprecedented acetyl bromide mediated Nazarov reaction.

Authors:  Philip Magnus; Wesley A Freund; Eric J Moorhead; Trevor Rainey
Journal:  J Am Chem Soc       Date:  2012-03-28       Impact factor: 15.419

3.  Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).

Authors:  D Engelmeier; F Hadacek; T Pacher; S Vajrodaya; H Greger
Journal:  J Agric Food Chem       Date:  2000-04       Impact factor: 5.279

4.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

5.  Novel flavaglines displaying improved cytotoxicity.

Authors:  Frédéric Thuaud; Nigel Ribeiro; Christian Gaiddon; Thierry Cresteil; Laurent Désaubry
Journal:  J Med Chem       Date:  2010-12-13       Impact factor: 7.446

6.  Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata.

Authors:  Li Pan; Leonardus B S Kardono; Soedarsono Riswan; Heebyung Chai; Esperanza J Carcache de Blanco; Caroline M Pannell; Djaja Doel Soejarto; Thomas G McCloud; David J Newman; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2010-10-12       Impact factor: 4.050

Review 7.  Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy.

Authors:  Soyoung Kim; Angela A Salim; Steven M Swanson; A Douglas Kinghorn
Journal:  Anticancer Agents Med Chem       Date:  2006-07       Impact factor: 2.505

8.  Nazarov cyclization initiated by peracid oxidation: the total synthesis of (+/-)-rocaglamide.

Authors:  John A Malona; Kevin Cariou; Alison J Frontier
Journal:  J Am Chem Soc       Date:  2009-06-10       Impact factor: 15.419

9.  Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

Authors:  Frédéric Thuaud; Yohann Bernard; Gülen Türkeri; Ronan Dirr; Geneviève Aubert; Thierry Cresteil; Aurélie Baguet; Catherine Tomasetto; Yuri Svitkin; Nahum Sonenberg; Canan G Nebigil; Laurent Désaubry
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  Flavaglines and triterpenoids from the leaves of Aglaia forbesii.

Authors:  Nantiya Joycharat; Harald Greger; Otmar Hofer; Ekarin Saifah
Journal:  Phytochemistry       Date:  2007-08-20       Impact factor: 4.072
View more
  44 in total

1.  Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.

Authors:  Janet L Oblinger; Sarah S Burns; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Exp Neurol       Date:  2017-06-10       Impact factor: 5.330

Review 2.  Current status and contemporary approaches to the discovery of antitumor agents from higher plants.

Authors:  Garima Agarwal; Peter J Blanco Carcache; Ermias Mekuria Addo; A Douglas Kinghorn
Journal:  Biotechnol Adv       Date:  2019-01-08       Impact factor: 14.227

3.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

4.  Total Syntheses of the Isomeric Aglain Natural Products Foveoglin A and Perviridisin B: Selective Excited-State Intramolecular Proton-Transfer Photocycloaddition.

Authors:  Wenyu Wang; Anthony Clay; Retheesh Krishnan; Neil J Lajkiewicz; Lauren E Brown; Jayaraman Sivaguru; John A Porco
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-13       Impact factor: 15.336

Review 5.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  A Douglas Kinghorn; Esperanza J Carcache DE Blanco; David M Lucas; H Liva Rakotondraibe; Jimmy Orjala; D Doel Soejarto; Nicholas H Oberlies; Cedric J Pearce; Mansukh C Wani; Brent R Stockwell; Joanna E Burdette; Steven M Swanson; James R Fuchs; Mitchell A Phelps; Lihui Xu; Xiaoli Zhang; Young Yongchun Shen
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

6.  Rocaglates as dual-targeting agents for experimental cerebral malaria.

Authors:  David Langlais; Regina Cencic; Neda Moradin; James M Kennedy; Kodjo Ayi; Lauren E Brown; Ian Crandall; Michael J Tarry; Martin Schmeing; Kevin C Kain; John A Porco; Jerry Pelletier; Philippe Gros
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

7.  Chinese herb derived-Rocaglamide A is a potent inhibitor of pancreatic cancer cells.

Authors:  Baochun Wang; Yixiong Li; Fengbo Tan; Zhanxiang Xiao
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

8.  Oxidopyrylium [5+2] Cycloaddition Chemistry: Historical Perspective and Recent Advances (2008-2018).

Authors:  Lauren P Bejcek; Ryan P Murelli
Journal:  Tetrahedron       Date:  2018-04-05       Impact factor: 2.457

9.  Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

Authors:  Janet L Oblinger; Sarah S Burns; Elena M Akhmametyeva; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; Beth Miles-Markley; Aaron C Moberly; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

10.  Cyclopenta[b]benzofuran and Secodammarane Derivatives from the Stems of Aglaia stellatopilosa.

Authors:  Nuraqilah Othman; Li Pan; Michele Mejin; Julian C L Voong; Hee-byung Chai; Caroline M Pannell; A Douglas Kinghorn; Tiong C Yeo
Journal:  J Nat Prod       Date:  2016-03-14       Impact factor: 4.050
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.